Bar Harbor's 15min chart sees KDJ Golden Cross, bullish Marubozu formation.
ByAinvest
Friday, Sep 19, 2025 11:23 am ET1min read
ADVB--
Key features of the A+PerfusC™ platform include 8 independent channels per plate, compatibility with 96/384 well plates for high-throughput screening, and microscope mounting capability. The platform has completed internal testing and validation, with mass production development currently underway. The launch targets the growing global 3D cell culture market, valued at $2.32 billion in 2025 and projected to reach $4.71 billion by 2030, with a CAGR of 15.6% [1].
Advanced Biomed Inc. has demonstrated a commitment to innovation in the biomedical sector through its product portfolio, which includes A+Pre, AC-1000, A+CellScan, and A+SCDrop, along with corresponding biochips and immunostaining kits. The company's focus on microfluidic technology for cancer detection and treatment underscores its strategic position in the healthcare industry.
BHB--
The 15-minute chart for Bar Harbor recently exhibited a bullish trend, as evidenced by the KDJ Golden Cross and Bullish Marubozu at 09/19/2025 11:15. This suggests that the momentum of the stock price is shifting towards the upside and has the potential to continue increasing. The market is currently controlled by buyers, which indicates a likely continuation of the bullish momentum.
Advanced Biomed Inc. (ADVB), a leading innovator in biomedical technology, has announced the launch of its latest product, A+PerfusC™, an integrated perfusion 3D cell culture platform designed for precision medicine and drug discovery applications. The system features a compact, all-in-one design that supports up to 12 days of continuous, hands-free culture with a capacity for 4,800 tumor spheroids per plate [1].Key features of the A+PerfusC™ platform include 8 independent channels per plate, compatibility with 96/384 well plates for high-throughput screening, and microscope mounting capability. The platform has completed internal testing and validation, with mass production development currently underway. The launch targets the growing global 3D cell culture market, valued at $2.32 billion in 2025 and projected to reach $4.71 billion by 2030, with a CAGR of 15.6% [1].
Advanced Biomed Inc. has demonstrated a commitment to innovation in the biomedical sector through its product portfolio, which includes A+Pre, AC-1000, A+CellScan, and A+SCDrop, along with corresponding biochips and immunostaining kits. The company's focus on microfluidic technology for cancer detection and treatment underscores its strategic position in the healthcare industry.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet